ProCE Banner Activity

Second-line Therapies in PV: Determining the Optimal Strategy After Hydroxyurea Failure

Slideset Download
In this downloadable slideset, Raajit K. Rampal, MD, PhD, reviews optimal second-line management strategies for patients with polycythemia vera, with a focus on those who have demonstrated an intolerance or inadequate response to hydroxyurea.

Released: December 14, 2017

Expiration: December 13, 2018

No longer available for credit.

Share

Faculty

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Incyte

Faculty Disclosure

Primary Author

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Incyte and funds for research support from Constellation.